<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04951557</url>
  </required_header>
  <id_info>
    <org_study_id>Benchpit</org_study_id>
    <nct_id>NCT04951557</nct_id>
  </id_info>
  <brief_title>Setting Benchmarks for Transsphenoidal Resection of Pituitary Adenomas</brief_title>
  <official_title>Setting Benchmarks for Transsphenoidal Resection of Pituitary Adenomas - An Analysis of Standardized Outcome References From an International Multicentre Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To conduct a retrospective multicenter cohort study to define benchmark values for best&#xD;
      achievable outcomes following transsphenoidal resection of pituitary adenomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Surgeons strive for the best possible outcome of their surgeries with the greatest possible&#xD;
      chance for recovery of the patients. Therefore, monitoring and quality improvement is&#xD;
      increasingly important in surgery. For this purpose, different concepts were developed with&#xD;
      the aim to assess best achievable results for several surgical procedures and reduce&#xD;
      unwarranted variation between different centers. The concept of a benchmark establishes&#xD;
      reference values which represents the best possible outcome of high-volume centers and can be&#xD;
      used for comparison and improvement. In the past years, the concept of benchmarking attaches&#xD;
      greater importance in the field of healthcare, especially in surgery. Benchmark values are&#xD;
      established within a patients' cohort for which the best possible outcome can be expected. To&#xD;
      date, no valid concept exists to describe the outcome of patients after transsphenoidal&#xD;
      resection of pituitary adenomas. The aim of our study is the establishment of robust and&#xD;
      standardized outcome references after transsphenoidal surgery. After successful implantation&#xD;
      of benchmarks from an international cohort of renowned centers, these data serve as reference&#xD;
      values for the evaluation of novel surgical techniques and comparisons among centers or&#xD;
      future clinical trials.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Reoperation</measure>
    <time_frame>up to two weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CSF leak</measure>
    <time_frame>up to two weeks</time_frame>
    <description>Requiring intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Epistaxis</measure>
    <time_frame>up to two weeks</time_frame>
    <description>Requiring intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Meningitis</measure>
    <time_frame>up to two weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Diabetes insipidus</measure>
    <time_frame>up to two weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>SIADH</measure>
    <time_frame>up to two weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cerebral vasospasm</measure>
    <time_frame>up to two weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>New hypopituitarism</measure>
    <time_frame>up to two weeks</time_frame>
    <description>Requiring hormone replacement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Normalization of hormone levels</measure>
    <time_frame>up to two weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>New neurological deficit</measure>
    <time_frame>up to two weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative change of vision</measure>
    <time_frame>up to two weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Need for ICU care</measure>
    <time_frame>up to two weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of stay</measure>
    <time_frame>up to two weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>up to two weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Readmission to hospital</measure>
    <time_frame>At 6 months follow up</time_frame>
    <description>Related to transsphenoidal surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrolyte imbalance</measure>
    <time_frame>At 6 months follow up</time_frame>
    <description>Requiring drug treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>New hypopituitarism</measure>
    <time_frame>At 6 months follow up</time_frame>
    <description>Requiring hormone replacement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>New neurological deficit</measure>
    <time_frame>At 6 months follow up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CSF leak</measure>
    <time_frame>At 6 months follow up</time_frame>
    <description>Requiring intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Termination of hypersecretion</measure>
    <time_frame>At 6 months follow up</time_frame>
    <description>If applicable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MRI resection control</measure>
    <time_frame>At 6 months follow up</time_frame>
    <description>If applicable</description>
  </primary_outcome>
  <other_outcome>
    <measure>Age</measure>
    <time_frame>At time of surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Gender</measure>
    <time_frame>At time of surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Body mass index</measure>
    <time_frame>At time of surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>ASA score</measure>
    <time_frame>At time of surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Hormone replacement</measure>
    <time_frame>At time of surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Neurological deficit</measure>
    <time_frame>At time of surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Previous therapy</measure>
    <time_frame>At time of surgery</time_frame>
    <description>None, transsphenoidal surgery, pharmacotherapy, radiotherapy</description>
  </other_outcome>
  <other_outcome>
    <measure>Tumour size</measure>
    <time_frame>At time of surgery</time_frame>
    <description>Microadenoma, Macroadenoma</description>
  </other_outcome>
  <other_outcome>
    <measure>Knosp grade</measure>
    <time_frame>At time of surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Tumour extension</measure>
    <time_frame>At time of surgery</time_frame>
    <description>Intraventricular extension, sinus cavernous invasion</description>
  </other_outcome>
  <other_outcome>
    <measure>Histology</measure>
    <time_frame>At time of surgery</time_frame>
    <description>According to 2017 WHO classification</description>
  </other_outcome>
  <other_outcome>
    <measure>Operating method</measure>
    <time_frame>Surgery</time_frame>
    <description>Endoscopy, microscopy, 3D-video microscopy, hybrid</description>
  </other_outcome>
  <other_outcome>
    <measure>Operating duration</measure>
    <time_frame>Surgery</time_frame>
    <description>minutes</description>
  </other_outcome>
  <other_outcome>
    <measure>Gross total resection</measure>
    <time_frame>Surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Blood transfusion</measure>
    <time_frame>Surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Repair of CSF leak</measure>
    <time_frame>Surgery</time_frame>
    <description>None, muscle/fascial patch, fibrin alone, mucosal flap, fat, other technique</description>
  </other_outcome>
  <other_outcome>
    <measure>Nasal tamponade</measure>
    <time_frame>Surgery</time_frame>
  </other_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Pituitary Adenoma</condition>
  <condition>Pituitary Tumor</condition>
  <condition>Pituitary Diseases</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transsphenoidal resection</intervention_name>
    <description>Transsphenoidal resection of pituitary adenoma</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who went through transsphenoidal resection of pituitary adenoma at high-volume&#xD;
        centres&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who went through transsphenoidal resection of pituitary adenoma&#xD;
&#xD;
          -  Including high-volume centres with ≥50 cases per year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Richard Drexler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franz L Ricklefs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jörg Flitsch, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard Drexler, MD</last_name>
    <phone>004915222816461</phone>
    <email>r.drexler@uke.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jörg Flitsch, MD</last_name>
    <email>flitsch@uke.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Drexler, MD</last_name>
      <email>r.drexler@uke.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 17, 2021</study_first_submitted>
  <study_first_submitted_qc>June 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsklinikum Hamburg-Eppendorf</investigator_affiliation>
    <investigator_full_name>Richard Drexler</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Pituitary Neoplasms</mesh_term>
    <mesh_term>Pituitary Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

